Exosens
€59.20Change from previous close: +0.17%Absolute change: +€0.10
Valuation
Data as of October 4, 2026
Valuation multiples
- Market cap
- €2.97B
- Enterprise value
- €3.21B
- P/E (trailing 12 months)
- 149.5
- Forward P/E
- 24.2
- PEG
- 1.28
- Price/book
- 6.58
- Price/sales
- 5.92
- EV/EBITDA
- 30.6
- EV/revenue
- 6.40
Profitability and growth
- Gross margin
- 60.1%
- Operating margin
- 12.9%
- Net margin
- 6.0%
- ROE
- 12.7%
- ROA
- 6.2%
- ROIC
- 10.3%
- Revenue growth (year over year)
- 15.3%
- Earnings growth (year over year)
- -45.1%
Financial health
- Total cash
- €69.23M
- Total debt
- €269.47M
- Debt/equity
- 0.60
- Current ratio
- 2.35
- Quick ratio
- 1.32
- Altman Z-Score
- 4.81
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- €0.30
- Dividend yield
- 0.5%
- Payout ratio
- 76.4%
- Ex-dividend date
- May 27, 2026
Analysts and estimates
- Average price target
- €69.70
- Median price target
- €69.50
- High price target
- €75.00
- Low price target
- €63.00
- Analysts with a price target
- 10
- Consensus
- Buy
- Forward EPS
- €2.41
- EPS estimate, current year
- €1.95
Shares and trading
- Beta
- 0.85
- Average volume
- 80.57K
- Shares outstanding
- 50.91M
- Float
- 32.83M
- Institutional ownership
- 47.3%
- Insider ownership
- 31.3%